DUBLIN–(BUSINESS WIRE)–The “Anti-CD279 (PD-1) Antibody – Pipeline Insight, 2022” clinical trials has been added to ResearchAndMarkets.com’s offering.
This “Anti-CD279 (PD-1) Antibody – Pipeline Insight, 2022” report provides comprehensive insights about 40+ companies and 40+ pipeline drugs in Anti-CD279 (PD-1) Antibody pipeline landscape.
It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Anti-CD279 (PD-1) Antibody – Pipeline Insight, 2022 report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Anti-CD279 (PD-1) Antibody pipeline landscape is provided which includes the disease overview and Anti-CD279 (PD-1) Antibody treatment guidelines.
The assessment part of the report embraces, in depth Anti-CD279 (PD-1) Antibody commercial assessment and clinical assessment of the pipeline products under development.
In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Anti-CD279 (PD-1) Antibody collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
The companies and academics are working to assess challenges and seek opportunities that could influence Anti-CD279 (PD-1) Antibody R&D. The therapies under development are focused on novel approaches to treat/improve Anti-CD279 (PD-1) Antibody.
Anti-CD279 (PD-1) Antibody Emerging Drugs Chapters
This segment of the Anti-CD279 (PD-1) Antibody report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Anti-CD279 (PD-1) Antibody Emerging Drugs
IBI308: Innovent Biologics
IBI308/ Sintilimab is a fully human monoclonal antibody that blocking programmed death protein-1. Innovent holds the global intellectual property rights of IBI308. Currently IBI308 has been approved for marketing by the NMPA. Acting as an immune checkpoint inhibitor by targeting PD-1, IBI308 boosts the immune response against tumor cells and inhibits the immune escape of tumor cells. It is currently in Phase III for Acral Melanoma, Nasopharyngeal Neoplasms, and Gastric Cancer. It is being developed by Innovent Biologics.
Tislelizumab: BeiGene
Tislelizumab (BGB-A317) is a humanized IgG4 anti-PD-1 monoclonal antibody specifically designed to minimize binding to FcγR on macrophages. In pre-clinical studies, binding to FcγR on macrophages has been shown to compromise the anti-tumor activity of PD-1 antibodies through activation of antibody-dependent macrophage-mediated killing of T effector cells. Tislelizumab is being developed as a monotherapy and in combination with other therapies for the treatment of a broad array of both solid tumor and hematologic cancers.
Anti-CD279 (PD-1) Antibody: Therapeutic Assessment
This segment of the report provides insights about the different Anti-CD279 (PD-1) Antibody drugs segregated based on following parameters that define the scope of the report.
Major Players in Anti-CD279 (PD-1) Antibody
There are approx. 40+ key companies which are developing the therapies for Anti-CD279 (PD-1) Antibody. The companies which have their Anti-CD279 (PD-1) Antibody drug candidates in the most advanced stage, i.e. Phase III include, Innovent Biologics.
Key Players
- GlaxoSmithKline
- Innovent Biologics
- BeiGene
- Shanghai Junshi Biosciences
Key Products
- Dostarlimab
- Sintilimab
- Tislelizumab
- JS-003
- JS-201
- Toripalimab
Key Topics Covered:
Introduction
Executive Summary
Anti-CD279 (PD-1) Antibody: Overview
- Causes
- Mechanism of Action
- Signs and Symptoms
- Diagnosis
- Disease Management
Pipeline Therapeutics
- Comparative Analysis
Therapeutic Assessment
- Assessment by Product Type
- Assessment by Stage and Product Type
- Assessment by Route of Administration
- Assessment by Stage and Route of Administration
- Assessment by Molecule Type
- Assessment by Stage and Molecule Type
Late Stage Products (Phase III)
- Comparative Analysis
IBI308: Innovent Biologics
- Product Description
- Research and Development
- Product Development Activities
Mid Stage Products (Phase II)
- Comparative Analysis
JS-201: Shanghai Junshi Biosciences
- Product Description
- Research and Development
- Product Development Activities
Early stage products (Phase I)
- Comparative Analysis
JS-003: Shanghai Junshi Biosciences
- Product Description
- Research and Development
- Product Development Activities
Preclinical stage products
- Comparative Analysis
Drug Name: Company Name
- Product Description
- Research and Development
- Product Development Activities
Inactive Products
- Comparative Analysis
Anti-CD279 (PD-1) Antibody Key Companies
Anti-CD279 (PD-1) Antibody Key Products
Anti-CD279 (PD-1) Antibody- Unmet Needs
Anti-CD279 (PD-1) Antibody- Market Drivers and Barriers
Anti-CD279 (PD-1) Antibody- Future Perspectives and Conclusion
Anti-CD279 (PD-1) Antibody Analyst Views
Anti-CD279 (PD-1) Antibody Key Companies
Appendix
For more information about this clinical trials report visit https://www.researchandmarkets.com/r/k9th0q
Contacts
ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900